Drug maker tracks Real-World results for blood cancer treatment
NCT ID NCT06581848
Summary
This study is monitoring the safety and real-world effectiveness of the drug Elranatamab in Korean patients with advanced multiple myeloma. It will enroll about 150 adults who have already received at least three prior treatments for their cancer. The goal is to gather information on side effects and how well the drug works in everyday clinical practice, outside of a controlled trial setting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.